Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Vipoma 1Uterine Cervical Dysplasia 1Squamous Intraepithelial Lesions 1Somatostatinoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, AIDS-Related 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Insulinoma 1Glucagonoma 1Gastrinoma 1Congenital Abnormalities 1Carcinoma, Islet Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 15Vincristine 13Prednisone 13Rituximab 12Doxorubicin 11Etoposide 10Radiotherapy 9Methotrexate 6Filgrastim 6Cytarabine 6Gemcitabine 5Cisplatin 5VAP-cyclo protocol 4Granulocyte Colony-Stimulating Factor 4ibritumomab tiuxetan 3Peripheral Blood Stem Cell Transplantation 3Methylprednisolone 3Leucovorin 3Immunohistochemistry 3Ifosfamide 3Gene Expression Profiling 3Dexamethasone 3pegfilgrastim 2merphos 2fludarabine 2axicabtagene ciloleucel 2Watchful Waiting 2Specimen Handling 2Mesna 2Magnetic Resonance Spectroscopy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Lymphoma, Large B-Cell, Diffuse × Biological Therapy × Clear all
NCT00310128 2016-02-03

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

AIDS Malignancy Consortium

Phase 2 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, AIDS-Related, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡